T1	PROC 46 63	Estudio de fase 2
T2	CHEM 67 73	BA3011
T3	PROC 77 88	monoterapia
#1	AnnotatorNotes T3	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T4	CHEM 110 119	nivolumab
#2	AnnotatorNotes T4	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	LIVB 123 140	pacientes adultos
T6	Age 133 140	adultos
T7	DISO 145 188	cáncer de pulmón no microcítico metastásico
#3	AnnotatorNotes T7	C4744562; Metastatic Lung Non-Small Cell Carcinoma; Neoplastic Process
T8	Neg_cue 162 164	no
T9	Negated 165 176	microcítico
T10	PROC 211 228	Estudio de fase 2
T11	PROC 245 259	administración
#4	AnnotatorNotes T11	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T12	CHEM 263 281	mecbotamab vedotin
T13	CHEM 283 289	BA3011
T14	PROC 294 305	monoterapia
#5	AnnotatorNotes T14	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T15	CHEM 327 336	nivolumab
#6	AnnotatorNotes T15	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T16	LIVB 340 357	pacientes adultos
T17	Age 350 357	adultos
T18	DISO 362 405	cáncer de pulmón no microcítico metastásico
#7	AnnotatorNotes T18	C4744562; Metastatic Lung Non-Small Cell Carcinoma; Neoplastic Process
T19	Neg_cue 379 381	no
T20	Negated 382 393	microcítico
T21	DISO 427 454	progresión de la enfermedad
#8	AnnotatorNotes T21	C0242656; Disease Progression; Pathologic Function
T22	PROC 466 477	tratamiento
#9	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	CHEM 485 515	inhibidor del PD-1/L1, el EGFR
T24	PROC 521 524	ALK
T25	DISO 527 539	intolerancia
T26	PROC 548 559	tratamiento
#10	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	DISO 583 599	Cáncer de pulmón
#11	AnnotatorNotes T27	C0242379; Malignant neoplasm of lung; Neoplastic Process | C0684249; Carcinoma of lung; Neoplastic Process
T28	DISO 626 677	Cáncer de pulmón de células no pequeñas metastásico
T29	Neg_cue 654 656	no
T30	Negated 657 665	pequeñas
T31	LIVB 708 717	pacientes
#12	AnnotatorNotes T31	C0030705; Patients; Patient or Disabled Group
T32	DISO 737 768	cáncer de pulmón no microcítico
#13	AnnotatorNotes T32	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T33	Neg_cue 754 756	no
T34	Negated 757 768	microcítico
T35	DISO 770 774	CPNM
#14	AnnotatorNotes T35	C0007131; Non-Small Cell Lung Carcinoma; Neoplastic Process
T36	DISO 812 823	metastásico
#15	AnnotatorNotes T36	C4255448; Metastasis; Pathologic Function
T37	PROC 836 867	histológica y/o citológicamente
T38	Age 877 885	≥18 años
T39	PHYS 897 910	Función renal
#16	AnnotatorNotes T39	C0232804; Renal function; Organ or Tissue Function
T40	PHYS 923 939	Función hepática
T41	PHYS 952 972	Función hematológica
T42	Duration 1108 1124	al menos 3 meses
T43	DISO 1154 1165	Cardiopatía
#17	AnnotatorNotes T43	C0018799; Heart Diseases; Disease or Syndrome
T44	DISO 1209 1219	metástasis
#18	AnnotatorNotes T44	C0027627; Neoplasm Metastasis; Neoplastic Process | C2939419; Secondary Neoplasm; Neoplastic Process
T45	Neg_cue 1220 1223	sin
T46	Negated 1224 1233	controlar
T47	ANAT 1240 1264	sistema nervioso central
#19	AnnotatorNotes T47	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T48	ANAT 1266 1269	SNC
#20	AnnotatorNotes T48	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T49	PROC 1274 1285	Tratamiento
#21	AnnotatorNotes T49	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T50	CHEM 1300 1326	derivado de la auristatina
T51	Neg_cue 1340 1343	sin
T52	Negated 1344 1352	conjugar
T53	CHEM 1405 1410	vinca
T54	DISO 1430 1450	reacciones alérgicas
#22	AnnotatorNotes T54	C0020517; Hypersensitivity; Pathologic Function | C1527304; Allergic Reaction; Pathologic Function
T55	PROC 1466 1477	tratamiento
#23	AnnotatorNotes T55	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T56	CHEM 1482 1485	AcM
#24	AnnotatorNotes T56	C0003250; Monoclonal Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor
T57	Spec_cue 1508 1519	sospecha de
T58	DISO 1520 1527	alergia
#25	AnnotatorNotes T58	C0020517; Hypersensitivity; Pathologic Function
T59	Speculated 1520 1527	alergia
T60	DISO 1530 1542	intolerancia
T61	Speculated 1530 1542	intolerancia
T62	CHEM 1563 1575	medicamentos
#26	AnnotatorNotes T62	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0304228; Proprietary drug, NOS; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T63	PROC 1644 1673	intervención de cirugía mayor
T64	Duration 1694 1707	las 4 semanas
T65	PROC 1732 1746	administración
#27	AnnotatorNotes T65	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T66	CHEM 1750 1756	BA3011
T67	PROC 1800 1848	pruebas del virus de la inmunodeficiencia humana
T68	DISO 1850 1853	VIH
#28	AnnotatorNotes T68	C0458074; Human immunodeficiency virus (HIV) status; Finding
T69	DISO 1870 1897	inmunodeficiencia adquirida
#29	AnnotatorNotes T69	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T70	DISO 1899 1903	sida
#30	AnnotatorNotes T70	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T71	LIVB 1908 1953	Mujeres embarazadas o en período de lactancia
